Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Carcinoma, Endometrioid

Tundra lists 2 Carcinoma, Endometrioid clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT06468215

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Gender: FEMALE

Ages: Any - 45 Years

Updated: 2024-07-16

Carcinoma, Endometrioid
Fertility Preservation
RECRUITING

NCT05945407

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.

Gender: FEMALE

Ages: 18 Years - 45 Years

Updated: 2023-07-14

1 state

Endometrial Neoplasms
Endometrial Neoplasm Malignant
Endometrial Neoplasm Malignant Stage I
+2